Company intelligence / Profile preview
SynOx Therapeutics
Dublin, County Dublin, Irelandsynoxtherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
SynOx is conducting a registrational Phase 3 clinical trial called TANGENT for emactuzumab in TGCT. The first patients were dosed in October 2024. Emactuzumab has shown promising efficacy in patients with TGCT and has a well-tolerated safety profile[4].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Licensed emactuzumab from Roche (exclusive worldwide rights)[2]
Beyond the preview
Go deeper on SynOx Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynOx Therapeutics.